Evidence map›Paper›PMID 40630352›Full record

ArticleCureus2025

Rebound Hyperkalemia After Potassium Repletion in Thyrotoxic Periodic Paralysis: A Case Report and Review of Management Implications.

Daichi Matsui, Shin Mugikura, Takahiro Goshima, Noriyoshi Ishizuka, Naruhiro Jingushi, Norimichi Uenishi, Mitsunaga Iwata

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daichi MatsuiDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.
Shin MugikuraDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.
Takahiro GoshimaDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.
Noriyoshi IshizukaDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.
Naruhiro JingushiDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.
Norimichi UenishiDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.
Mitsunaga IwataDepartment of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyrotoxic periodic paralysis (TPP) is a potentially life-threatening complication of hyperthyroidism. It is characterized by hypokalemia-induced muscle weakness that typically begins in the proximal lower limbs and may progress to paralysis of all four extremities and involvement of the respiratory muscles. We present a case of a 37-year-old man with a history of TPP, presenting with acute muscle weakness and hypokalemia. The patient reported acute-onset bilateral lower extremity weakness from the previous day. Physical examination revealed normal deep tendon reflexes, but marked muscle weakness was observed in both lower limbs. Laboratory workup revealed severe hypokalemia at 2.1 mEq/L and thyrotoxicosis, while the electrocardiogram showed a prolonged QTc interval. The patient received thiamazole, potassium iodide, and propranolol for thyrotoxicosis and a total dose of 122 mEq of potassium repletion. His potassium level rose from 1.7 mEq/L to 5.6 mEq/L within six hours post-repletion cessation, highlighting the risk of rebound hyperkalemia and the importance of close monitoring. This case underscores the danger of rebound hyperkalemia after aggressive potassium repletion in TPP and supports a cautious, stepwise correction strategy.

Indexed as

endocrinologyhypokalemiapropranololrebound hyperkalemiathyrotoxic periodic paralysis

Identifiers

PMID40630352
PMCPMC12235673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.